No Data
No Data
No Data
No Data
No Data
Acumen Pharmaceuticals Presents First Comprehensive Clinical And Biomarker Data For Sabirnetug At American Academy Of Neurology 2024 Annual Meeting
Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker changesPresentation to be featured during AAN Emerging Science SessionCompany o
BenzingaApr 16 08:17 ET
13 Best Penny Stocks to Buy According to Billionaire Ken Griffin
Yahoo FinanceApr 8 17:38 ET
Lonza Enters Manufacturing Agreement for Acumen's Alzheimer's Disease Drug Candidate
Lonza Group (LONN.SW) and Acumen Pharmaceuticals signed a clinical development and commercialization deal for the latter's sabirnetug drug candidate, which is being studied for the treatment of Alzhei
MT NewswiresApr 4 11:35 ET
Express News | Acumen Pharmaceuticals Collaborates With Lonza Covering The Manufacture Of Sabirnetug (ACU193) For Alzheimer's Disease, For Clinical Development And Commercialization, If Approved
Moomoo 24/7Apr 4 08:03 ET
Analysts Offer Insights on Healthcare Companies: LAVA Therapeutics (LVTX), Acumen Pharmaceuticals (ABOS) and Advanced Medical Solutions (GB:AMS)
TipRanksApr 3 05:10 ET
Acumen Pharmaceuticals (ABOS) Upgraded to Buy: What Does It Mean for the Stock?
Yahoo FinanceMar 28 12:00 ET
JESSE JAMES8832 : i saw this over the weekend i thought it might be somethin worth lookin into also
TrytosaveabitOP JESSE JAMES8832: Yeah i believe that this has some pretty good potential by EOY, if not sooner? GL my man!
No Data
No Data